General Information of the Compound
Compound ID
CP0310354
Compound Name
Examorelin
    Show/Hide
Synonyms
EP-23905
Examorelin
Hexarelin
MF-6003
    Show/Hide
Structure
Formula
C47H58N12O6
Molecular Weight
887.059
Canonical SMILES
C[C@H](NC(=O)[C@@H](Cc1c(C)[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O
    Show/Hide
InChI
InChI=1S/C47H58N12O6/c1-27-34(33-15-7-9-17-37(33)54-27)23-41(58-44(62)35(49)22-31-25-51-26-53-31)45(63)55-28(2)43(61)57-40(21-30-24-52-36-16-8-6-14-32(30)36)47(65)59-39(20-29-12-4-3-5-13-29)46(64)56-38(42(50)60)18-10-11-19-48/h3-9,12-17,24-26,28,35,38-41,52,54H,10-11,18-23,48-49H2,1-2H3,(H2,50,60)(H,51,53)(H,55,63)(H,56,64)(H,57,61)(H,58,62)(H,59,65)/t28-,35-,38-,39+,40-,41+/m0/s1
    Show/Hide
InChIKey
RVWNMGKSNGWLOL-GIIHNPQRSA-N
Physicochemical Property
logP
1.33682
Rotatable Bonds
23
Heavy Atom Count
65
Polar Areas
300.89
Hydrogen Bond Donor Count
11
Hydrogen Bond Acceptor Count
9
Complexity
65

"RO5" indicates the cutoff set by lipinski's rule of five:

(1) Molecular weight less than 500 Dalton;

(2) xlogp less than 5;

(3) No more than 5 hbonddonor (Hydrogen Bond Donor Count);

(4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count);

(5) No more than 10 rotbonds (Rotatable Bond Count).

    Show/Hide
Click to Show/Hide the External Link(s) of This Compound
PubChem ID
CID: 6918297
SID: 15263465
ChEMBL ID
CHEMBL108335
Map of Molecular Bioactivity Related to the Compound
Map of Molecular Bioactivity Related to the Compound

Compound
Cell Line
Protein

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT01155, Growth hormone secretagogue receptor type 1
Cell-based Assay
Cell Line ID Cell Line Name Cell Line Organism
CL000009 LLC-PK1 Sus scrofa (Pig)  1
1
IC50 = 15.9 nM
   TI
   LI
   LO
   TS
Biochemical Assays
1 IC50 = 18 nM
Clinical Information about the Compound
Drug 1 ( Examorelin )
Drug Name Examorelin
Company Mediolanum Farmaceutici SpA
Indication
Growth hormone deficiency
Discontinued in Phase 2
Target(s)
Growth hormone-releasing hormone receptor (GHRHR)
Modulator